- Dec 30, 2008
NCT00644228 : Phase 3 - Lenalidomide and Dexamethasone + / - Bortezomib in NDMM - SWOG S0777
Phase III trial SWOG S0777 SWOG0777 0777 Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously...
389
- Dec 14, 2008
NCT00689936: Phase 3 - Lenalidomide+low dose dex vs Melphalan, Prednisone, Thalidomide in NDMM FIRST
FIRST study IFM 07-01 CC-5013-MM020 Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan,...
439
- Dec 6, 2008
NCT00602641: Phase 3: Melphalan, Prednisone, and Thalidomide or Lenalidomide in NDMM Myeloma
ECOG-E1A06 ECOG-ACRIN Cancer Research Group NCT00602641: Phase 3: Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating...
64
- Dec 3, 2008
NCT00609167: Phase 2: Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With NDMM
NCT00609167: Phase 2: Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma...
59
- Dec 26, 2007
NCT00430365: Phase 3 - IFM2005-02 - Maintenance Therapy Using Lenalidomide in Myeloma
IFM2005-02 Maintenance Therapy Using Lenalidomide in Myeloma (IFM2005-02) NCT00430365: Phase 3 - Maintenance Therapy Using Lenalidomide...
364
- Dec 21, 2007
NCT00507442: Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat NDMM EVOLUTION
EVOLUTION Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients (EVOLUTION)...
104